Navigation Links
KINAXO Completes Financing Round to Enhance Biomarker Development
Date:11/21/2009

Martinsried, Germany, November 20,2009 / b3c newswire / -KINAXO Biotechnologies GmbH announces the completion of a financing round, gaining two new investors in the company, Leifina and Conmit Invest. At the same time KINAXO reports that Jrgen Schumacher has been elected as a new member of the companys advisory board.


KINAXO shareholders Axel Ullrich, Hellmut Kirchner, Manfred Ferber as well as the companys institutional investors Mountain Partners, BioM, High-Tech Grnderfonds, the Max-Planck Society and the KfW ERP Start-Fonds also participated in this financing round. KINAXO will use the funds to develop novel biomarkers that allow stratification of cancer patients receiving targeted therapies.


KINAXOs CEO and co-founder Andreas Jenne said: There is little doubt that biomarkers will be one of the major drivers of pharmaceutical research and development in the 21st Century. Biomarkers have the potential to improve R&D efficiency and clinical success rates, save public health costs, and gain pharmaceutical companies a valuable advantage over their competitors. Following this trend we will make significant investments over the next few years to expand our phosphoproteomics services PhosphoScout and develop a novel class of biomarkers that help improve cancer therapies.


Horst Domdey, CEO of BioM, commented: KINAXO is in the right place at the right time. Today, biomarkers are more and more in demand to improve treatment options. With its unique phosphoproteomics platform that goes way beyond existing technologies, KINAXO is very well positioned in this rapidly growing market. Moreover, KINAXOs recent partnerships with Bayer and Roche underpin the industrys readiness to implement novel technologies turning personalized medicine into reality.

About KINAXO Biotechnologies GmbH
KINAXO is a privately-held biotechnology company based in Munich/Martinsried, Germany. KINAXO offers a unique technology tool box for drug mode-of-action analysis, cellular target profiling, target deconvolution, drug repositioning and biomarker identification. KINAXO maintains several collaborations with leading pharmaceutical companies, such as Bayer, Roche, Boehringer Ingelheim and Johnson & Johnson.


About KINAXOs PhosphoScout service
PhosphoScout is a quantitative phosphoproteomics service developed to investigate cellular signal transduction pathways and their response to drug treatment. It allows annotation and quantification of regulated phosphorylation sites in living cells, animal models and patient samples. Using state-of-the-art quantitative mass spectrometry up to 15,000 phosphorylation changes can be monitored in a single experiment, allowing system-wide modeling of cellular signaling events. Unlike immunoassays, PhosphoScout does not require antibodies for detection and thus enables unbiased phosphoproteome analyses across signaling pathways on a global scale.


About Leifina GmbH
Leifina is a diversified investment holding company managed by its founder Dr. Kurt Schwarz who held positions at Harvard Medical School, the Massachusetts General Hospital and Merck Sharp & Dohme. From 1990 to 2006 he was a member of the supervisory board of Schwarz Pharma. As a prominent private investor Schwarz is engaged in various biotechnology companies and private equity funds.

About Conmit Invest GmbH
Conmit invests in companies with exceptional prospects and outstanding management. Managing founder Hans-Milo Halhuber played a leading role in developing the German health care service market. From 1999 to 2009 Halhuber was Chairman of CURANUM, which under his leadership became Germanys biggest listed health care service company. As a serial entrepreneur Halhuber is actively involved in more than 20 companies.

About Dr. Jrgen Schumacher
Jrgen Schumacher is an internationally recognized German entrepreneur. He is a co-founder of Qiagen and principal founder of NewLab Bioquality, which he sold to Charles River Laboratories International in 2008. Besides being involved in several industry associations and other organizations, Schumacher is an experienced business angel who holds management and board positions in a number of biotechnology companies.

Contact
Dr. Andreas Jenne, CEO KINAXO Biotechnologies GmbH
Am Klopferspitz 19a, 82152 Martinsried, Germany
www.kinaxo.com

Phone: +49 89 46133630
Email:info@kinaxo.de


'/>"/>
b3c newswire

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue
3. KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
4. SyntheMed Completes $2.8 Million Equity Financing
5. Labwire Completes Its First Acquisition
6. bioMETRX, Inc. Completes Sequiam Asset Purchase
7. bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC
8. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
9. DOE Joint Genome Institute completes soybean genome
10. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
11. Lockheed Martin Team Completes Key Design Milestone on Federal Bureau of Investigations Next Generation Identification Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
Breaking Biology Technology: